SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
APVO reported Quarter ended September 30, 2026 results. The price and volatility reaction is pending.
APVOearnings

Earnings reactions, page 2

Aptevo Therapeutics Inc. (APVO) FY2026 earnings

November 16, 2026 · SharpeIQ Research Desk

Reported results

  • Mipletamig achieved a 79% remission rate (CR or CRi) in 14 evaluable TP53-mutated AML patients.
  • Ten of 47 evaluable frontline patients treated with mipletamig in combination with venetoclax and azacitidine proceeded to allogeneic stem cell transplantation.
  • Cash and cash equivalents totaled $8.3 million as of September 30, 2026.
  • Net loss for the third quarter of 2026 was $6.5 million.
  • The company completed a warrant inducement and private placement in August 2026 that generated gross proceeds of approximately $4.5 million.

Guidance

  • Study completion for the RAINIER trial is targeted by year-end 2026.
  • Regulatory interaction for mipletamig is planned for the first half of 2027.
  • Two preclinical molecules are expected to advance into investigational new drug (IND)-enabling studies in 2027.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-16 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →